- Conditions
- Keratosis
- Interventions
- Aldara (imiquimod) cream, 5%
- Drug
- Lead sponsor
- Graceway Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • Vista, California • Atlanta, Georgia + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1201–1224
of 5,392
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Cancer
- Interventions
- Talc
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 501 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2006
- U.S. locations
- 224
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 174 more
- Conditions
- Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant, Lip and Oral Cavity Squamous Cell Carcinoma, p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oral Cavity Verrucous Carcinoma, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Interventions
- Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
- Drug · Radiation · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 679
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 450 more
- Conditions
- Cystic Fibrosis
- Interventions
- inhaled mannitol, Placebo comparator
- Drug
- Lead sponsor
- Syntara
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 28
- States / cities
- Tucson, Arizona • Hartford, Connecticut • Jacksonville, Florida + 23 more
- Conditions
- Breast Cancer
- Interventions
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 2,778 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 134
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 84 more
- Conditions
- COVID-19
- Interventions
- Obeldesivir, Obeldesivir Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 12 Years to 64 Years
- Enrollment
- 2,011 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 108
- States / cities
- Alabaster, Alabama • Chandler, Arizona • Tucson, Arizona + 60 more
- Conditions
- Growth
- Interventions
- Cow's milk protein infant formula, Partially hydrolyzed protein infant formula
- Other
- Lead sponsor
- Mead Johnson Nutrition
- Industry
- Eligibility
- 10 Days to 14 Days
- Enrollment
- 244 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 10 more
- Conditions
- Infection, Human Immunodeficiency Virus I, HIV Infection
- Interventions
- GW873140, Kaletra (lopinavir/ritonavir)
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fountain Valley, California + 23 more
- Conditions
- Peanut Allergy
- Interventions
- AR101 powder provided in capsules & sachets, Placebo powder provided in capsules & sachets
- Biological
- Lead sponsor
- Aimmune Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 55 Years
- Enrollment
- 555 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 49
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 39 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- CC-220, Placebo
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 30 more
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Myelodysplastic Syndrome, Childhood Renal Cell Carcinoma, Chronic Myelomonocytic Leukemia, Clear Cell Renal Cell Carcinoma, de Novo Myelodysplastic Syndrome, Metastatic Renal Cell Cancer, Previously Treated Myelodysplastic Syndrome, Progression of Multiple Myeloma or Plasma Cell Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Renal Medullary Carcinoma, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
- Interventions
- Fludarabine Phosphate, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Mycophenolate Mofetil
- Drug · Radiation · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Stanford, California • Atlanta, Georgia + 5 more
- Conditions
- Advanced Cancer
- Interventions
- RBS2418, Pembrolizumab, Other approved anti-cancer therapy
- Drug
- Lead sponsor
- Riboscience, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Palo Alto, California + 11 more
- Conditions
- Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Colorectal Cancer
- Interventions
- SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab
- Drug
- Lead sponsor
- Biosplice Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Aurora, Colorado • Scarborough, Maine + 11 more
- Conditions
- Non-Hodgkin's B-cell Lymphoma
- Interventions
- MT-3724
- Drug
- Lead sponsor
- Molecular Templates, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • New York, New York • Houston, Texas
- Conditions
- Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
- Interventions
- Adavosertib, Paclitaxel, Carboplatin, Gemcitabine, PLD
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Female only
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 18
- States / cities
- Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 14 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Intismeran autogene, Pembrolizumab, Placebo
- Biological · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 868 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2035
- U.S. locations
- 68
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Yuma, Arizona + 55 more
- Conditions
- Congestive Heart Failure
- Interventions
- Irbesartan, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 4,128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 57 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
- Conditions
- Joint Damage
- Interventions
- Febuxostat, Placebo for Febuxostat
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 56
- States / cities
- Mesa, Arizona • Tucson, Arizona • Burbank, California + 53 more
- Conditions
- Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia
- Interventions
- Azacitidine, Laboratory Biomarker Analysis, Lenalidomide, Vorinostat
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 280
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 217 more
- Conditions
- Breast Neoplasms, Neoplasms, Hormone-dependent
- Interventions
- atamestane, toremifene, letrozole, aromatase inhibition, hormone therapy, endocrine therapy, antiestrogen therapy
- Drug · Procedure
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 865 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 17
- States / cities
- Lake Havasu City, Arizona • Tucson, Arizona • Greenbrae, California + 14 more
- Conditions
- Non-Small-Cell Lung Carcinoma NSCLC
- Interventions
- MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel + Carboplatin, Gemcitabine + Cisplatin, Gemcitabine + Carboplatin, Pemetrexed + Cisplatin, Pemetrexed + Carboplatin, Tremelimumab
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 35
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 28 more
- Conditions
- Asthma
- Interventions
- lebrikizumab, placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 70
- States / cities
- Pell City, Alabama • Scottsdale, Arizona • Tucson, Arizona + 63 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Tiotropium, Salmeterol
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 653 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 17 more